An interventional study of Human dehydrated umbilical cord allograft and Placebo in Shoulder Injury, Shoulder Sprain and Supraspinatus Tear, sponsored by MiMedx Group, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-18.
Sponsored by MiMedx Group, Inc. · Not applicable, Interventional, and Treatment
To determine the effectiveness of human dehydrated umbilical cord allograft in standard open rotator cuff repair as assessed by the American Shoulder and Elbow Surgeons (ASES) score 12 months post-op.
114 studies on the registry are indexed under Shoulder Injuries; 31 are open to participants now.
This study's enrollment of 25 is below the median of 55 across 65 interventional studies indexed under Shoulder Injuries.
Browse Shoulder Injuries studies →MiMedx Group, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects who meet ANY of the following criteria will be excluded from the study:
Shoulder pain primarily attributed to any of the following:
Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
Other: Human dehydrated umbilical cord allograft
Open Rotator Cuff Repair with standard suture repair
Other: Placebo
human dehydrated umbilical cord allograft
Open rotator cuff surgery with standard suture repair
ASES score
The primary endpoint of the study is the number of subjects achieving a 20% increase from baseline in the overall ASES score at 12 months post-op.
Time frame: 12 months
Constant Murley Score
Comparison of Constant scores between the two groups at each study time point
Time frame: 12 months
Shoulder range of motion
Assessment of the change in the range of motion of the shoulder joint for both treatment groups at each study time point.
Time frame: 12 months
VAS Pain scores
Change in patient reported pain from baseline
Time frame: 12 months
Incidence of tendon re-tear
Incidence of supraspinatus tendon re-tear in the two treatment groups as assessed by review of MRI scans by independent radiologists
Time frame: 12 months
Incidence of adverse events
Incidence of adverse events
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MiMedx Group, Inc.